OCT生物标志物作为地塞米松植入剂治疗糖尿病黄斑水肿的功能结局预测因子
这项多中心回顾性观察队列研究纳入299眼(284例)接受玻璃体内地塞米松植入剂治疗的糖尿病黄斑水肿患者,评估基线OCT特征与视力应答的相关性。结果显示视网膜下液存在、无高反射灶及IS-OS层完整均预测更好的视力结局,初治眼较难治眼视力增益更多,但OCT预测价值不受此分类影响。
要点
- 视网膜下液存在(OR 1.98)、无高反射灶(OR 3.66)、IS-OS层完整(OR 2.09)均预测地塞米松植入剂治疗后更好视力结局。
- 初治糖尿病黄斑水肿眼较难治眼视力增益更多(P < 0.001),但OCT特征的预测价值不因该分类而异。
- 谱域OCT有助于识别糖尿病黄斑水肿的多种影像学表现。
核心结论
- 在糖尿病黄斑水肿眼中,具备视网膜下液、无高反射灶及IS-OS层连续的眼对地塞米松植入剂应答更好。
- 这些发现提示需进一步研究OCT与代谢生物标志物的组合。
研究设计与样本
- 多中心、回顾性、观察性队列研究,共纳入284例患者的299眼,其中初治209眼、难治90眼。
- 基线最佳矫正视力为最小分辨角对数视力表0.3至1.0之间。
- 评估地塞米松植入剂治疗前OCT扫描中的视网膜下液、囊样改变大小与位置、IS-OS连续性、高反射灶数量与位置、玻璃体黄斑界面异常及视网膜前膜。
- 在基线及地塞米松植入剂治疗后1、2、4个月记录最佳矫正视力与中心黄斑厚度。
- 采用广义估计方程分析OCT指标与视力结局的相关性。
主要发现
- 视网膜下液存在(OR 1.98;95%CI 1.23-3.20;P=0.01)、无高反射灶(OR 3.66;95%CI 1.40-9.62;P=0.01)及IS-OS层完整(OR 2.09;95%CI 1.30-3.37;P=0.003)均预测地塞米松植入剂治疗后更好的视力结局。
- 初治糖尿病黄斑水肿眼较难治眼视力增益更多(P < 0.001),但OCT表现的预测价值不因该分类而异。
关键数值与推荐
- 视网膜下液存在:OR 1.98(95%CI 1.23-3.20;P=0.01),预测更好的视力结局。
- 无高反射灶:OR 3.66(95%CI 1.40-9.62;P=0.01),预测更好的视力结局。
- IS-OS层完整:OR 2.09(95%CI 1.30-3.37;P=0.003),预测更好的视力结局。
- 初治眼较难治眼视力增益更多(P < 0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Identification and characterization of patients with diabetic macular edema (DME) are important for individualizing treatment and optimizing outcome. We investigated OCT biomarkers for DME treated by intravitreal dexamethasone (DEX) implant. DESIGN: Multicenter, retrospective, observational cohort study. PARTICIPANTS: A total of 299 eyes from 284 patients treated with DEX implant for DME (naïve, n = 209; refractory, n = 90). Baseline best-corrected visual acuity (BCVA) was between 0.3 and 1.0 on a logarithm of minimum angle of resolution visual chart. METHODS: The OCT scans previous to DEX implants were evaluated for submacular fluid, size and location of cystoid changes, inner segment-outer segment (IS-OS) continuity, quantity and location of hyperreflective foci (HRF), vitreomacular interface abnormalities, and epiretinal membrane. The BCVA and central macular thickness were recorded at baseline and at 1, 2, and 4 months after treatment with DEX implants. Correlations between OCT measures and visual outcome were analyzed using the generalized estimating equations procedure. MAIN OUTCOME MEASURES: The correlation between spectral-domain (SD) OCT measures at baseline and BCVA response (mean change from baseline; categorized improvement [<5, 5-9, or ≥10; Early Treatment Diabetic Retinopathy Study letters] in BCVA) after treatment with a DEX implant. RESULTS: The presence of subretinal fluid (odds ratio [OR], 1.98; 95% confidence interval [CI], 1.23-3.20; P = 0.01), absence of HRF (OR, 3.66; 95% CI, 1.40-9.62; P = 0.01), and integrity of the IS-OS layer (OR, 2.09; 95% CI, 1.30-3.37; P = 0.003) were all predictive of better visual outcome after treatment with DEX implants. Although eyes with naïve DME gained more vision than refractory eyes (P < 0.001), the predictive value of OCT findings did not differ according to this classification. CONCLUSIONS: Spectral-domain OCT is useful in identifying various imaging findings in DME. Among eyes with DME, those with submacular fluid, no HRF, and a continuous IS-OS layer responded better to DEX implants than those without these features. These findings call for further study of combinations of OCT and metabolic biomarkers.
引用
- Zur D, Iglicki M, Busch C, et al. OCT Biomarkers as Functional Outcome Predictors in Diabetic Macular Edema Treated with Dexamethasone Implant. Ophthalmology. 2017. PMID: 28935399. doi:10.1016/j.ophtha.2017.08.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。